Danoprevir: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
'''Danoprevir''' | == Danoprevir == | ||
[[File:Danoprevir.svg|thumb|right|Chemical structure of Danoprevir]] | |||
'''Danoprevir''' is an investigational [[antiviral drug]] that was developed for the treatment of [[hepatitis C virus]] (HCV) infection. It is a [[protease inhibitor]] that targets the [[NS3/4A serine protease]], an enzyme essential for the replication of the hepatitis C virus. | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Danoprevir works by inhibiting the | Danoprevir works by inhibiting the NS3/4A serine protease, which is a critical enzyme in the HCV replication cycle. By blocking this enzyme, danoprevir prevents the virus from processing its polyprotein into functional viral proteins, thereby halting viral replication. | ||
== Clinical | == Clinical Development == | ||
Danoprevir was developed by [[Genentech]], a member of the [[Roche Group]]. It has been studied in combination with other antiviral agents, including [[pegylated interferon]] and [[ribavirin]], as part of a [[direct-acting antiviral]] (DAA) regimen for the treatment of chronic hepatitis C. | |||
== | === Clinical Trials === | ||
Danoprevir has undergone several phases of clinical trials to evaluate its safety, efficacy, and pharmacokinetics. Early trials demonstrated that danoprevir, in combination with other DAAs, could achieve high rates of sustained virologic response (SVR) in patients with HCV genotype 1 infection. | |||
== | == Side Effects == | ||
The most common side effects observed in clinical trials of danoprevir include [[fatigue]], [[headache]], [[nausea]], and [[diarrhea]]. As with other protease inhibitors, there is a potential for drug-drug interactions, and caution is advised when co-administering danoprevir with other medications. | |||
== | == Related Pages == | ||
* [[Hepatitis C]] | * [[Hepatitis C]] | ||
* [[Protease inhibitor]] | * [[Protease inhibitor (pharmacology)]] | ||
* [[ | * [[Direct-acting antiviral]] | ||
* [[ | * [[Genentech]] | ||
[[Category: | [[Category:Antiviral drugs]] | ||
[[Category:Hepatitis C]] | [[Category:Hepatitis C]] | ||
Latest revision as of 04:06, 13 February 2025
Danoprevir[edit]
Danoprevir is an investigational antiviral drug that was developed for the treatment of hepatitis C virus (HCV) infection. It is a protease inhibitor that targets the NS3/4A serine protease, an enzyme essential for the replication of the hepatitis C virus.
Mechanism of Action[edit]
Danoprevir works by inhibiting the NS3/4A serine protease, which is a critical enzyme in the HCV replication cycle. By blocking this enzyme, danoprevir prevents the virus from processing its polyprotein into functional viral proteins, thereby halting viral replication.
Clinical Development[edit]
Danoprevir was developed by Genentech, a member of the Roche Group. It has been studied in combination with other antiviral agents, including pegylated interferon and ribavirin, as part of a direct-acting antiviral (DAA) regimen for the treatment of chronic hepatitis C.
Clinical Trials[edit]
Danoprevir has undergone several phases of clinical trials to evaluate its safety, efficacy, and pharmacokinetics. Early trials demonstrated that danoprevir, in combination with other DAAs, could achieve high rates of sustained virologic response (SVR) in patients with HCV genotype 1 infection.
Side Effects[edit]
The most common side effects observed in clinical trials of danoprevir include fatigue, headache, nausea, and diarrhea. As with other protease inhibitors, there is a potential for drug-drug interactions, and caution is advised when co-administering danoprevir with other medications.
